For those considering or having undergone weight loss surgery, understanding the potential long-term effects on your health is crucial.
A recent study has shed light on the use of proton pump inhibitors (PPIs) after two common bariatric surgeries: laparoscopic Roux-en-Y gastric bypass (L-RYGB) and sleeve gastrectomy (L-SG).
The findings are particularly relevant for individuals concerned about gastroesophageal reflux disease (GERD) and its management post-surgery.
The study looked at 17,740 patients in Denmark who underwent either L-RYGB or L-SG between 2008 and 2018. The researchers aimed to understand how patients use PPIs long-term to manage acid reflux and GERD after these surgeries.
Key findings
One of the most significant findings from the study is that patients who underwent sleeve gastrectomy (L-SG) had a much higher risk of starting and continuing PPI treatment compared to those who had a Roux-en-Y gastric bypass (L-RYGB).
Specifically, the study found that the risk of initiating PPI use after L-SG was seven times higher than after L-RYGB. Additionally, patients who had sleeve gastrectomy were also more likely to continue using PPIs over the long term.
This increase in PPI use among L-SG patients is closely linked to a higher incidence of GERD. The study noted that the risk of being diagnosed with GERD was significantly higher after L-SG compared to L-RYGB. This is consistent with previous findings that L-SG, while effective for weight loss, can lead to new or worsening acid reflux in many patients.
Why does this matter?
For those who have undergone or are considering L-SG, these findings are particularly important. GERD is a chronic condition that can lead to serious complications if not properly managed.
The need for long-term PPI use after L-SG suggests that patients may experience ongoing reflux symptoms, which could affect their quality of life and potentially lead to more serious conditions like Barrett’s oesophagus.
On the other hand, L-RYGB appears to be a better option for individuals who are concerned about GERD, as it not only helps with weight loss but also seems to lower the risk of developing acid reflux issues post-surgery.
Early detection and management of GERD
For those already dealing with GERD, early detection and proper management are key to preventing further complications. This is where tools like Peptest can play a crucial role.
Peptest is a simple, non-invasive test that detects the presence of pepsin, an enzyme associated with acid reflux, in your saliva. By identifying GERD early, especially after procedures like L-SG, you can take proactive steps to manage your symptoms and reduce the need for long-term medication use.
Peptest detects pepsin — the stomach enzyme that marks reflux — in a saliva sample. Collected at home, analysed in our UK laboratory, results back within 48 hours.
- Results in 48 hours
- No GP referral needed
- UK laboratory
Recent Comments